Sophie Davies, a new mother in Suffolk, turned to a FDA‑approved transcranial direct‑current stimulation headset after a month of escalating Prozac doses failed to lift her depression and obsessive‑compulsive symptoms. The lightweight device, sold over the counter in the UK for $530, delivers a mild electric current that targets brain circuits without inducing seizures today.

Flow Neuroscience, the Swedish firm behind the device, secured U.S. approval in December after a 2024 Empower study showed modest gains on the Hamilton depression scale. Although the primary outcome was labeled a “minor” improvement, 58% of treated participants responded and 45% reached full remission versus 38% and 22% in the control arm today investors.

The FDA’s decision legitimizes tDCS as a medical therapy, potentially reducing reliance on selective serotonin reuptake inhibitors that now treat about one in six Americans. With a modest price point and home‑based convenience, the headset could reshape psychiatry’s drug‑centric model, offering a new tool for clinicians and patients seeking alternatives in 2026 market growth potential.

Yet the Empower trial’s moderate benefit and high placebo detectability raise doubts about tDCS’s clinical potency. Regulators and investors will watch whether Flow can price the device—its list price remains undisclosed—and expand its market share beyond early adopters, as the company navigates competition from established neuromodulation modalities like TMS in 2026 industry growth potential today.